In RA IKKβ is a key regulator of synovial inflammation [6] and the importance of the canonical NF-κB pathway in arthritis is underlined by the beneficial effects of specific IKKβ inhibition in preclinical models of arthritis [6,7] and the common and successful use of anti-TNF therapy in RA, one of the main target genes of the canonical NF-κB pathway. This evidence concerns the gene NFKB1 and arthritic joint disease.